102
Participants
Start Date
December 17, 2019
Primary Completion Date
January 31, 2041
Study Completion Date
January 31, 2041
pegfilgrastim
It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
RECRUITING
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RECRUITING
Levine Cancer Institute, Charlotte
Atrium Health Levine Cancer Institute
OTHER
Wake Forest University Health Sciences
OTHER